Wednesday, 7 February 2018

Aurobindo Pharma May Post 18% Growth In Q3 Profit, US Business Seen Up 12%

Healthcare company Aurobindo Pharma is expected to report a 18 percent growth year-on-year in third quarter profit at Rs 682 crore compared to Rs 578.6 crore in year-ago.

Revenue growth and steady margins may lead to YoY profit growth.

Revenue from operations in Q3 may increase 11 percent to Rs 4,328.4 crore from Rs 3,906.2 crore in corresponding quarter of last fiscal, according to average of estimates of analysts polled by CNBC-TV18.

For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory

1 comment:

  1. CASH PREMIUM CALL: SELL SUPREMEIND BELOW 1235 TARGETS 1220 / 1200 / 1170 STOPLOSS 1250

    CASH PREMIUM UPDATE: SUPREMEIND CALL #SECOND TARGETS (1200) HAS ACHIEVED BOOK MORE PROFIT


    Get Best High light investment research call

    ReplyDelete